ERAP1, ERAP2, and Two Copies of HLA-Aw19 Alleles Increase the Risk for Birdshot Chorioretinopathy in HLA-A29 Carriers.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
01 11 2021
Historique:
entrez: 2 11 2021
pubmed: 3 11 2021
medline: 23 11 2021
Statut: ppublish

Résumé

Birdshot chorioretinopathy (BSCR) is strongly associated with HLA-A29. This study was designed to elucidate the genetic modifiers of BSCR in HLA-A29 carriers. We sequenced the largest BSCR cohort to date, including 286 cases and 108 HLA-A29-positive controls to determine genome-wide common and rare variant associations. We further typed the HLA alleles of cases and 45,386 HLA-A29 controls of European ancestry to identify HLA alleles that associate with BSCR risk. Carrying a second allele that belongs to the HLA-Aw19 broad antigen family (including HLA-A29, -A30, -A31, and -A33) increases the risk for BSCR (odds ratio [OR] = 4.44; P = 2.2e-03). This result was validated by comparing allele frequencies to large HLA-A29-controlled cohorts (n = 45,386; OR > 2.5; P < 1.3e-06). We also confirm that ERAP1 and ERAP2 haplotypes modulate disease risk. A meta-analysis with an independent dataset confirmed that ERAP1 and ERAP2 haplotypes modulate the risk for disease at a genome-wide significant level: ERAP1-rs27432 (OR = 2.46; 95% confidence interval [CI], 1.85-3.26; P = 4.07e-10), an expression quantitative trait locus (eQTL) decreasing ERAP1 expression; and ERAP2-rs10044354 (OR = 1.95; 95% CI, 1.55-2.44; P = 6.2e-09), an eQTL increasing ERAP2 expression. Furthermore, ERAP2-rs2248374 that disrupts ERAP2 expression is protective (OR = 0.56; 95% CI, 0.45-0.70; P = 2.39e-07). BSCR risk is additively increased when combining ERAP1/ERAP2 risk genotypes with two copies of HLA-Aw19 alleles (OR = 13.53; 95% CI, 3.79-54.77; P = 1.17e-05). The genetic factors increasing BSCR risk demonstrate a pattern of increased processing, as well as increased presentation of ERAP2-specific peptides. This suggests a mechanism in which exceeding a peptide presentation threshold activates the immune response in choroids of A29 carriers.

Identifiants

pubmed: 34727153
pii: 2778043
doi: 10.1167/iovs.62.14.3
pmc: PMC8572510
doi:

Substances chimiques

HLA-A Antigens 0
HLA-A19 antigen 0
HLA-A29 antigen 0
Minor Histocompatibility Antigens 0
Aminopeptidases EC 3.4.11.-
ERAP1 protein, human EC 3.4.11.-
ERAP2 protein, human EC 3.4.11.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3

Références

Hum Mol Genet. 2018 Dec 15;27(24):4333-4343
pubmed: 30215709
Hum Immunol. 2018 Feb;79(2):109-116
pubmed: 29183862
Curr Opin Ophthalmol. 2014 Nov;25(6):488-94
pubmed: 25211040
Am J Ophthalmol. 1982 Aug;94(2):147-58
pubmed: 6956239
Nat Biotechnol. 2020 Feb;38(2):199-209
pubmed: 31844290
Ocul Immunol Inflamm. 2011 Dec;19(6):397-400
pubmed: 22106906
PLoS Genet. 2009 Dec;5(12):e1000766
pubmed: 20011102
Arthritis Rheumatol. 2015 Nov;67(11):2957-65
pubmed: 26238044
Mol Cell Proteomics. 2018 Aug;17(8):1564-1577
pubmed: 29769354
Nature. 2020 Oct;586(7831):749-756
pubmed: 33087929
Blood. 2008 Aug 1;112(3):708-10
pubmed: 18502829
Nat Genet. 2010 Jun;42(6):508-14
pubmed: 20453842
Sci Rep. 2018 Jul 10;8(1):10398
pubmed: 29991817
Hum Mol Genet. 2014 Nov 15;23(22):6081-7
pubmed: 24957906
Nat Genet. 2011 Jul 10;43(8):761-7
pubmed: 21743469
Genes Immun. 2008 Apr;9(3):249-58
pubmed: 18340360
Orphanet J Rare Dis. 2016 May 12;11(1):61
pubmed: 27175923
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
BMC Bioinformatics. 2014 Jan 29;15:30
pubmed: 24475911
Clin Ophthalmol. 2014;8:73-81
pubmed: 24379650
Am J Ophthalmol. 1980 Jan;89(1):31-45
pubmed: 7356785
Ann N Y Acad Sci. 2006 Oct;1079:1-8
pubmed: 17130525
Hum Immunol. 2019 May;80(5):325-334
pubmed: 30797823
Mol Cell Proteomics. 2018 Jul;17(7):1308-1323
pubmed: 29632046
Nat Genet. 2018 Sep;50(9):1335-1341
pubmed: 30104761
Nat Genet. 2008 Aug;40(8):955-62
pubmed: 18587394
J Biol Chem. 2017 Jun 9;292(23):9680-9689
pubmed: 28446606
Mol Cell Proteomics. 2015 Jul;14(7):1770-80
pubmed: 25892735
Nat Genet. 2010 Nov;42(11):985-90
pubmed: 20953190
Hum Immunol. 2016 Mar;77(3):233-237
pubmed: 26826444
Genes Immun. 1999 Nov;1(2):120-9
pubmed: 11196658
PLoS One. 2013 Jun 06;8(6):e64683
pubmed: 23762245
Am J Ophthalmol. 2006 Jan;141(1):185-7
pubmed: 16386995
Nat Genet. 2021 Jul;53(7):1097-1103
pubmed: 34017140
Clin Rheumatol. 2017 Oct;36(10):2261-2266
pubmed: 28801811
Br J Ophthalmol. 2017 Jul;101(7):851-855
pubmed: 28314830
BMC Genomics. 2014 May 01;15:325
pubmed: 24884790
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
PLoS Genet. 2010 Oct 14;6(10):e1001157
pubmed: 20976248
Front Immunol. 2018 Oct 30;9:2463
pubmed: 30425713
Hum Immunol. 2014 Jun;75(6):570-7
pubmed: 24530754
Am J Ophthalmol. 1992 Jan 15;113(1):33-5
pubmed: 1728143
J Immunol. 2019 Sep 15;203(6):1629-1635
pubmed: 31405953
Mol Immunol. 2020 May;121:7-19
pubmed: 32135401
Ann Rheum Dis. 2016 Dec;75(12):2208-2211
pubmed: 27217550
Am J Ophthalmol. 2021 Aug;228:65-71
pubmed: 33845003
Eye (Lond). 2012 Jun;26(6):862-5
pubmed: 22402699
Nat Commun. 2019 Nov 28;10(1):5436
pubmed: 31780650

Auteurs

Sahar Gelfman (S)

Regeneron Genetics Center, Tarrytown, New York, United States.

Dominique Monnet (D)

Université de Paris, Hôpital Cochin, service d'ophtalmologie, Paris, France.

Ann J Ligocki (AJ)

Regeneron Pharmaceuticals, Tarrytown, New York, United States.

Thierry Tabary (T)

University of Reims Champagne Ardennes, Reims, France.

Arden Moscati (A)

Regeneron Genetics Center, Tarrytown, New York, United States.

Xiaodong Bai (X)

Regeneron Genetics Center, Tarrytown, New York, United States.

Jan Freudenberg (J)

Regeneron Genetics Center, Tarrytown, New York, United States.

Blerta Cooper (B)

Regeneron Pharmaceuticals, Tarrytown, New York, United States.

Jack A Kosmicki (JA)

Regeneron Genetics Center, Tarrytown, New York, United States.

Sarah Wolf (S)

Regeneron Genetics Center, Tarrytown, New York, United States.

Manuel A R Ferreira (MAR)

Regeneron Genetics Center, Tarrytown, New York, United States.

John Overton (J)

Regeneron Genetics Center, Tarrytown, New York, United States.

Jonathan Weyne (J)

Regeneron Pharmaceuticals, Tarrytown, New York, United States.

Eli A Stahl (EA)

Regeneron Genetics Center, Tarrytown, New York, United States.

Aris Baras (A)

Regeneron Genetics Center, Tarrytown, New York, United States.

Carmelo Romano (C)

Regeneron Pharmaceuticals, Tarrytown, New York, United States.

Jacques H M Cohen (JHM)

University of Reims Champagne Ardennes, Reims, France.

Giovanni Coppola (G)

Regeneron Genetics Center, Tarrytown, New York, United States.

Antoine Brézin (A)

Université de Paris, Hôpital Cochin, service d'ophtalmologie, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH